Global biosimulation market projected to reach $14.05 billion by 2032 with high growth potential.
From GlobeNewswire: 2025-06-25 08:30:00
The global Biosimulation Market was valued at USD 3.44 billion in 2023 and is projected to reach USD 14.05 billion by 2032, with a CAGR of 16.94% during the forecast period. High demand for predictive modeling tools in drug discovery, investments in R&D, and support from regulators are driving market growth.
The U.S. biosimulation market was valued at USD 1.25 billion in 2023 and is expected to reach USD 5.08 billion by 2032, growing at a CAGR of 16.83%. North America leads the market due to its strong healthcare infrastructure and high pharmaceutical research expenditure.
Major players in the biosimulation market include Certara, Dassault Systèmes, Schrödinger, and Simulation Plus. These companies offer a range of software and services for drug development, disease modeling, and more.
The software segment holds the largest share of the biosimulation market, with 61% in 2023, due to its critical role in predictive modeling and clinical trials. The drug development segment dominated the market with a 54% share, showcasing the importance of biosimulation in optimizing drug design and reducing clinical trial failures.
The oncology segment leads the biosimulation market due to the rising demand for innovative cancer therapies. Biosimulation tools are used to simulate tumor progression and optimize drug dosing, helping to improve treatment outcomes and reduce development costs.
North America currently dominates the biosimulation market, but Asia-Pacific is expected to show the fastest growth, driven by increasing healthcare spending and pharmaceutical manufacturing hubs in China, India, and South Korea.
SNS Insider offers detailed reports on the Biosimulation Market, providing insights into market size, key players, and growth trends. With a focus on delivering accurate market data and consumer insights, SNS Insider aims to help clients make informed decisions in a rapidly changing market landscape.
Read more at GlobeNewswire: Biosimulation Market Set to Reach USD 14.05 Billion by